CIK 0001799191 · Accelerated filer<br>Smaller reporting company
Starling Oncology, Inc.
Sign in to watch- Tickers
- STLN DFPH
- Exchange
- Nasdaq, OTC
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843562323
- Phone
- 562-735-3226
- Business address
- 18000 STUDEBAKER RD, SUITE 800, CERRITOS, CA, 90703
- Former names
- Oncology Institute, Inc., DFP HEALTHCARE ACQUISITIONS CORP.
Securities
- STLN Common Stock Nasdaq
- STLNW Warrant Nasdaq
- DFPH Common stock OTC
- Open-market buys, last 90 days
- $176,273
- in 1 filing
- Open-market sales, last 90 days
- $13,322,043
- in 2 filings, $1.9M under 10b5-1 plans
Net −$13,145,770. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-03 | Hively Brad Director | Option exercise | +105,320 | $0.48 | $51K | 1,501,881 |
| 2025-06-03 | Hively Brad Director | Option exercise | +131,297 | $1.87 | $246K | 1,633,178 |
| 2025-06-03 | Hively Brad Director | Option exercise | +946,460 | $0.85 | $804K | 2,579,638 |
| 2025-06-03 | Hively Brad Director | Sale | −1,867,605 | $2.87 | $5.4M | 712,033 |
| 2025-06-03 | Hively Brad Director | Sale | −108,532 | $2.87 | $312K | 603,501 |
| 2025-06-03 | Hively Brad Director | Option exercise · Non-Qualified Stock Option (right to buy) | +684,528 | 0 | ||
| 2025-06-03 | Hively Brad Director | Option exercise · Non-Qualified Stock Option (right to buy) | +105,320 | 0 | ||
| 2025-06-03 | Hively Brad Director | Option exercise · Non-Qualified Stock Option (right to buy) | +131,297 | 0 | ||
| 2025-06-03 | Hively Brad Director | Option exercise · Non-Qualified Stock Option (right to buy) | +946,460 | 0 | ||
| 2025-05-21 | Langsam Jeffrey Chief Clinical Officer | Grant or award | +57,380 | 57,380 | ||
| 2025-05-21 | Virnich Daniel Chief Executive Officer | Returned to the company | −20,388 | $2.68 | $55K | 1,787,309 |
| 2025-05-21 | Podnos Yale Chief Medical Officer | Returned to the company | −1,801 | $2.68 | $5K | 234,336 |
| 2025-05-21 | Carter Robert Ross Chief Financial Officer | Returned to the company | −1,601 | $2.68 | $4K | 235,174 |
| 2025-05-21 | Castle Jeremy Chief Operating Officer | Returned to the company | −5,636 | $2.68 | $15K | 247,031 |
| 2025-05-20 | M33 Growth I L.P. Director | Sale | −1,796,468 | $2.71 | $4.9M | 14,624,233 |
| 2025-05-20 | M33 Growth I L.P. Director | Sale | −203,532 | $2.71 | $552K | 1,349,048 |
| 2025-03-31 | Podnos Yale Chief Medical Officer | Grant or award | +157,088 | 236,137 | ||
| 2025-03-31 | Carter Robert Ross Chief Financial Officer | Grant or award | +197,368 | 236,775 | ||
| 2025-03-31 | Castle Jeremy Chief Operating Officer | Grant or award | +162,281 | 252,667 | ||
| 2025-03-31 | Virnich Daniel Chief Executive Officer | Grant or award | +1,083,334 | 1,807,697 |
Page 6 of 8 · 157 trades